JONES!LAB NEWS

EMBO_Logo.jpg

DR. GRIGAITIS EARNS AN EMBO POSTDOCTORAL FELLOWSHIP

July 2022

We congratulate our postdoctoral research teammate, Rokas for his new fellowship! The EMBO Postdoctoral Fellowship supports internationally mobile postdoctoral researchers in Europe and around the world. Rokas' exceptional research plan pursues the discovery and characterization of CRISPR nucleases and other phage-derived interference machinery with high throughput methods. His efforts bridge the Jones and Pausch laboratories at the EMBL Partnership Institute.

natcomm.jpg

RESULTS PUBLISHED IN NATURE COMMUNICATIONS

March 2022

In the March issue of Nature Communications, we share the results of recent collaborative efforts with Martin Depken's team at TU Delft. It describes a new kinetic model for how CRISPR-Cas9 operates and how it discriminates its DNA targets. This work was made possible through inter-disciplinary collaborations with the Depken and Finkelstein labs.

LBTA.jpg

LITHUANIAN BIOTECH ASSOCIATION INTERVIEW

January 26, 2022

Dr. Monika Paule, CEO of CasZyme and board member of the Lithuanian Biotechnology Association, interviews our team's leader about how Lithuania can attract top level scientists. Find out about Dr. Jones' transition to Lithuania from the US for science and adventure!

RG_photo (1).jpeg

DR. ROKAS GRIGAITIS JOINS THE TEAM

January 10, 2022

Dr. Rokas Grigaitis is the first postdoctoral researcher on our team: He joins us from ETH Zurich, where he studied DNA repair with Dr. Joao Matos. His shared appointment with our collaborator,  Dr. Pausch, means his expertise will make a big contribution to the EMBL Partnership Institute. Learn more about Rokas on out Teams page.

Welcome, Rokas!

CMN.png

CRISPR MEDICINE NEWS WEBINAR: OFF-TARGETS II

December 8, 2021

CMN invited Dr. Jones to share his work and thoughts on off-targeting by CRISPR nucleases. He first described the available tools and future goals for assessing the off-targets of gene editors. Later, he showcased how the CHAMP and NucleaSeq tools help us identify off-targets and mechanisms of Cas9 and Cas12a.

Thermo-Fisher-Scientific-Mokslo-Diena-2021-Spalvotas-baltas-fonas-permatomas_edited_edited.png

THERMO FISHER SCIENTIFIC'S SCIENCE DAY

November 10th, 2021

Dr. Jones was invited to share his research at Thermo Fisher Scientific's Mokslo Diena (Science Day). This annual event brings together scientists and researchers from across Lithuania and the world. Follow the link below to learn more!

Image by Hannah Busing

THREE MASTERS STUDENTS JOIN THE TEAM

October 1st, 2021

We are excited to share that our laboratory team has grown! Lina Krikščikaitė joins us from the Genetics program, while Ieva Jaskovikaite and Daniel Adelakin join us from the Molecular Biotechnology program. Learn more about these talented scientists on our Team page. Welcome, everyone!

Urte-Glibaustkaite-Picture.jpg

OUR FIRST UNDERGRADUATE RESEARCHER JOINS THE TEAM

September 1, 2021

Urtė Glibauskaitė is a third-year student Vilnius University's Biochemistry program. She's our very first addition to the team, and we're excited to have her! For the next two years, she'll help us make new discoveries in CRISPR biochemistry while completing her Bachelors thesis. Learn more about her on our Team page. Welcome, Urtė!

Stephen_Jones_GMC_v.jpg

DR. JONES JOINS THE FACULTY OF THE EMBL PARTNERSHIP INSTITUTE AT VILNIUS UNIVERSITY'S LIFE SCIENCES CENTER

July 2021

Dr Stephen Jones has started working at the VU LSC and he will lead a scientific group at the newly established sui generis operational unit of VU LSC, EMBL Partnership Institute.
Stephen’s group will create and research new genome editing tools.

Stephen got his PhD in 2015 in Brown University, Providence, USA. He is coming to LSC from University of Texas, Austin, where he worked very productively in the group of Prof. Ilya Finkelstein researching ageing processes of cells and epigenetic regulation.

Stephen got his works published in the most prestigious scientific publications, such as Cell, PNAS and others. Together with other well-known scientists of this field, such as the Nobel winner J. Doudna, Stephen Jones has established a platform that allows massive parallel kinetic profiling of CRISPR nucleases. The platform is called NucleaSeq and was presented in the Nature Biotechnology in 2020.

‘We expect that the experience of the new group leader and his group would significantly expand our presence in genome editing research areas, contribute towards the development of interdisciplinary research and enhance collaboration between scientists at VU LSC and EMBL. I wish all the best for the new research group. Stephen, welcome to the Life Sciences Center of Vilnius University!’ says Dr Gintaras Valinčius, Director of VU LSC.

NatBio.png

RESULTS PUBLISHED IN NATURE BIOTECH

September 2020

In the September issue of Nature Biotechnology, we shared our research describing the specificity of natural and engineered CRISPR nucleases. We showcased our newly-developed "next-generation" biochemistry method - NucleaSeq - that captures nuclease kinetics and cleavage outcomes at nucleotide-resolution. The data and models presented in this publication help genome engineers select a nuclease that matches their goals and predict its activity.

This work was made possible through inter-disciplinary collaborations with the Finkelstein, Press and Doudna labs.